Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets
U.S. Product Revenue Increased Five-fold During the Third Quarter
ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and ezetimibe) in Germany, the Largest European Market
Conference Call and Webcast today, November 2nd at 4:30 P.M. Eastern Time
#ESPR "reported financial results for the third quarter ended September 30, 2020, and provided a business update.
2020 Third Quarter Financial Results
As of September 30, 2020, cash, cash equivalents, restricted cash and investment securities available-for-sale totaled $215.7 million compared with $300.7 million at June 30, 2020.
Total revenue was $3.8 million for the third quarter of 2020. This amount includes approximately $3.3 million of net product sales and $0.5 million in partner reimbursement for the third quarter of 2020. This compares to total revenue of $1.0 million for the third quarter of 2019. The increase in revenue was primarily related to U.S. net product sales of NEXLETOL and NEXLIZET.
Research and development expenses were $35.3 million for the third quarter of 2020, compared to $48.3 million for the comparable period in 2019. The decrease was primarily attributable to a decline in costs related to the completion of enrollment of our CLEAR CVOT, which was fully enrolled during the third quarter of 2019" (see press release HERE).
See our ESPR AmpCards to learn more.